Business description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Management board & Supervisory board
| CEO |
| Dr. Osamu Okuda |
| Management board |
| Toshiaki Itagaki |
| Supervisory board |
| Dr. Osamu Okuda, Dr. Hisafumi Yamada, Toshiaki Itagaki, Dr. Mariko Y Momoi, Dr. Fumio Tateishi, Hideo Teramoto, Dr. Christoph Franz, Dr. James H. Sabry, Teresa A. Graham |
Company data
| Name: |
Chugai Pharmaceutical Co., Ltd. |
| Address: |
1-1 Nihonbashi-Muromachi 2-Chome Chuo-ku,Tokyo 103-8324 |
| Phone: |
+81-(0)3-3281-6611 |
| Fax: |
+81-(0)3-3281-6607 |
| E-mail: |
-
|
| Internet: |
https://www.chugai-pharm.co.jp/english/index.html |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
- |
| End of financial year: |
12/31 |
| Free Float: |
- |
| IPO date: |
- |
Investor relations
| Name: |
- |
| IR phone: |
+81-(0)3-3273-0554 |
| IR Fax: |
+81-(0)3-3281-6607 |
| IR e-mail: |
-
|
